Targeting agents work by recognizing and binding to specific biomarkers present on the surface of target cells. These biomarkers can be overexpressed proteins, receptors, or other molecular structures unique to diseased cells, such as cancer cells. Upon binding, the nanoparticle can deliver its therapeutic payload directly to the target site, minimizing off-target effects and improving treatment efficacy.
